Genentech
Manufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
225 Binney St, Cambridge, Massachusetts,...Website
www.rituxan.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Genentech
RITUXAN (rituximab) is a prescription medication used to treat various conditions including Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Pemphigus Vulgaris (PV). It is indicated for adults and certain pediatric populations, combining with other therapies as necessary. The medication is associated with serious side effects, including infusion-related reactions and the potential reactivation of hepatitis B virus. RITUXAN is targeted towards healthcare providers for the management of these conditions in patients.Explore more
Popular SearchesGenentech IncRituxanBiogenSIC Code 28,283NAICS Code 32,325Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Genentech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Genentech launches new products
Genentech, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Genentech recently announced quarterly report
Funding: Get notified immidiatlly once Genentech has new funding data
Check if Genentech has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if Genentech is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Genentech
Click to see if Genentech had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Genentech
Find 2 more new buyers
Compare Similar Companies to Genentech
Compare insights from companies similar to Genentech, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Genentech
<$5M
1-10
Private
-
-
N/A
Company Profile Activity
Activity Insights
Genentech is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Genentech is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Genentech.
Genentech Tech Stack
A closer look at the technologies used by Genentech
See more technologies
Genentech News & Media
FDA Approves Genentech’s Rituxan (rituximab) in Children With Two Rare Blood Vessel Disorders
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan® (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in pediatric patients 2 years of age and older. GPA and MPA are rare, potentially life-threatening diseases affecting small- and medium-sized blood vessPhase III PEMPHIX Study Showed That Genentech’s Rituxan (Rituximab) is Superior to Standard of Care in Achieving Sustained Remission in Patients with Pemphigus Vulgaris
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive top line results from the Roche-sponsored Phase III PEMPHIX study evaluating the efficacy and safety of Rituxan® (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris (PV). The study met the primary endpoint, and demonstrated that Rituxan is superior to MMF in achieving sustained complete remission. “The PEFDA Grants Priority Review to Genentech’s Rituxan (Rituximab) in Children with Two Rare Blood Vessel Disorders
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for the use of Rituxan® (rituximab), in combination with glucocorticoids (GCC), for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children two years of age and older.Genentech to Present New Data from Its Industry-Leading Hematology Portfolio at the American Society of Hematology (ASH) 2018 Annual Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data for its approved and investigational medicines across a range of blood diseases, and including several first-in-class medicines, will be presented at the 60th American Society of Hematology (ASH) Annual Meeting from December 1-4 in San Diego. Ten Genentech medicines will be featured in more than 70 abstracts, including 25 oral presentations, across 15
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Genentech
Sign Up For FreeTo access detailed company insights
RITUXAN (rituximab) is a prescription medication used to treat various conditions including Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Pemphigus Vulgaris (PV). It is indicated for adults and certain pediatric populations, co... Read More
